

Blinded phase: CHAQ

The summary statistics for the CHAQ are shown for each treatment group for each scheduled visit in Table 1.

Table 1: CHAQ Score by treatment group by time point

| Visit | Adalimumab | | | | Placebo | | | | Total | | | |
|-----------|------------|---------|--------------|--------------------|---------|---------|--------------|--------------------|-------|---------|--------------|--------------------|
| | n | missing | Mean (SD) | Median (range) | n | missing | Mean (SD) | Median (range) | n | missing | Mean (SD) | Median (range) |
| Baseline | 59 | 1 | 0.52 (0.64) | 0.21 (0.00, 2.49) | 28 | 2 | 0.48 (0.49) | 0.45 (0.00, 1.57) | 87 | 3 | 0.51 (0.59) | 0.33 (0.00, 2.49) |
| 1 month | 59 | 1 | 0.41 (0.56) | 0.13 (0.00, 2.29) | 30 | 0 | 0.60 (0.55) | 0.55 (0.00, 1.61) | 89 | 1 | 0.47 (0.56) | 0.22 (0.00, 2.29) |
| 2 months | 57 | 1 | 0.38 (0.53) | 0.11 (0.00, 1.96) | 24 | 1 | 0.54 (0.59) | 0.45 (0.00, 2.32) | 81 | 2 | 0.43 (0.55) | 0.20 (0.00, 2.32) |
| 3 months | 54 | 2 | 0.36 (0.58) | 0.03 (0.00, 2.49) | 18 | 1 | 0.37 (0.47) | 0.19 (0.00, 1.50) | 72 | 3 | 0.36 (0.55) | 0.05 (0.00, 2.49) |
| 6 months | 45 | 3 | 0.36 (0.61) | 0.02 (0.00, 2.49) | 12 | 0 | 0.46 (0.63) | 0.11 (0.00, 2.00) | 57 | 3 | 0.38 (0.61) | 0.05 (0.00, 2.49) |
| 9 months | 39 | 3 | 0.35 (0.63) | 0.06 (0.00, 2.28) | 7 | 0 | 0.36 (0.57) | 0.09 (0.00, 1.58) | 46 | 3 | 0.35 (0.62) | 0.06 (0.00, 2.28) |
| 12 months | 34 | 0 | 0.33 (0.60) | 0.02 (0.00, 2.04) | 4 | 1 | 0.09 (0.15) | 0.02 (0.00, 0.31) | 38 | 1 | 0.31 (0.57) | 0.02 (0.00, 2.04) |
| 15 months | 26 | 1 | 0.43 (0.58) | 0.11 (0.00, 2.00) | 3 | 0 | 0.03 (0.04) | 0.01 (0.00, 0.07) | 29 | 1 | 0.39 (0.56) | 0.10 (0.00, 2.00) |
| 18 months | 22 | 1 | 0.30 (0.48) | 0.02 (0.00, 1.55) | 3 | 0 | 0.03 (0.05) | 0.01 (0.00, 0.09) | 25 | 1 | 0.27 (0.46) | 0.02 (0.00, 1.55) |